Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14198603 | 0.84 | KMT2A (0.79) | KMT2AMEN1ALDH1A1L3MBTL1POLB | |
| SCHEMBL11624141 | 0.76 | KMT2A (0.83) | KMT2AMEN1ALDH1A1L3MBTL1POLB | |
| SCHEMBL25017242 | 0.75 | RAB9A (0.68) | KMT2AMEN1ALDH1A1L3MBTL1POLB | |
| SCHEMBL14924020 | 0.74 | KMT2A (0.68) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL5237448 | 0.74 | HPGD (1.00) | KMT2AMEN1ALDH1A1L3MBTL1POLB | |
| SCHEMBL19002582 | 0.74 | TP53 (0.68) | KMT2AMEN1ALDH1A1L3MBTL1POLB | |
| SCHEMBL7837431 | 0.74 | HDAC8 (0.77) | KMT2AMEN1ALDH1A1L3MBTL1POLB | |
| SCHEMBL24069015 | 0.73 | KMT2A (0.71) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL21851982 | 0.73 | NPSR1 (0.80) | KMT2AMEN1ALDH1A1L3MBTL1POLB | |
| SCHEMBL11621200 | 0.73 | KMT2A (0.76) | KMT2AMEN1ALDH1A1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | CITY OF HOPE (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | CITY OF HOPE | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | TXN, TXN2, TXNRD3 | KMT2A 3189/4885MEN1 4275/4885ALDH1A1 3479/4885 |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | TXN, TXN2, TXNRD3 | KMT2A 3189/4885MEN1 4275/4885ALDH1A1 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.